Key result
Anthracycline or trastuzumab chemotherapy is linked to a ~4% LVEF decline over six months.
Why the study?
Does adjuvant chemotherapy (anthracycline or trastuzumab) cause left ventricular remodeling in low-cardiac-risk women with newly diagnosed nonmetastatic breast cancer?
Cohort (n=20)
Does adjuvant chemotherapy (anthracycline or trastuzumab) cause left ventricular remodeling in low-cardiac-risk women with newly diagnosed nonmetastatic breast cancer?
Absolute Event Rate: 60.41% vs 64.15%
p-value: p=<0.002
In low-cardiac-risk women with nonmetastatic breast cancer, adjuvant chemotherapy induces mild left ventricular dilation and a small decrease in ejection fraction over 6 months, without clinical evidence of heart failure.
No takes yet. Share an insight, caveat, or question.
Mild LV dilation and LVEF drop after chemotherapy may not indicate heart failure risk in low-risk patients; leaves open larger studies to refine surveillance.
Avelar et al. (2017) conducted a cohort in newly diagnosed nonmetastatic breast cancer (n=20). Anthracycline or trastuzumab chemotherapy vs. Baseline was evaluated on Left ventricular ejection fraction (%) (p=<0.002). Chemotherapy with anthracycline or trastuzumab in women with nonmetastatic breast cancer decreased left ventricular ejection fraction from 64.15% to 60.41% over 6 months (P<0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: